StockNews.com Initiates Coverage on Global Cord Blood (NYSE:CO)

Equities researchers at StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:COGet Free Report) in a research note issued to investors on Friday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

Shares of Global Cord Blood stock opened at $1.75 on Friday. Global Cord Blood has a 1 year low of $2.03 and a 1 year high of $5.50. The company has a market cap of $212.71 million, a P/E ratio of 2.73 and a beta of 0.16. The stock has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.35.

Global Cord Blood Company Profile

(Get Free Report)

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.

Further Reading

Receive News & Ratings for Global Cord Blood Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Cord Blood and related companies with MarketBeat.com's FREE daily email newsletter.